Arsenic trioxide (
As2O3) is both the most prevalent, naturally occurring inorganic arsenical threatening human health and an efficient therapeutic for
acute promyelocytic leukemia. Regretfully, As2O3-treated
cancer patients often suffer from hepatotoxicity. While effective
antioxidant and anticarcinogenic actions of
allicin have previously been demonstrated, studies indicating how
allicin affects As2O3-induced hepatotoxicity and
arsenic accumulation are lacking. Our study, for the first time, elaborates potential details of the hepatoprotective mechanisms of
allicin against As2O3-induced liver injury. Wistar rats were administrated
allicin (30 mg/kg) 1 h before
As2O3 (3 mg/kg) by daily gavage for 2 weeks. Our results indicate that
allicin ameliorated As2O3-induced
liver dysfunction, oxidative stress, and
arsenic accumulation in the liver. Meanwhile,
allicin decreased NF-κB level and upregulated expression of
proteins reduced by
As2O3 including nuclear factor erythroid 2-related factor 2 (Nrf2),
heme oxygenase 1,
nicotinamide adenine dinucleotide phosphate:
quinone oxidoreductase 1, and Krüppel-like
factor 9 (KLF9). In addition,
allicin promoted
B cell lymphoma-extra large expression and suppressed B cell lymphoma-2-associated X
protein levels regulated by
As2O3. However, neither
allicin nor
As2O3 affected
cytochrome P450 2E1 mRNA expression. In conclusion,
allicin attenuated As2O3-induced hepatotoxicity by activating the Nrf2 signaling pathway involving KLF9 to inhibit oxidative stress and apoptosis. Our findings elucidate a detailed mechanism by which
allicin provides protection against As2O3-induced liver injury and support its potential role as an adjunctive
therapy for patients suffering from chronic
arsenic exposure.